Dual GIP-GLP-2 Peptide for Bone Matrix Cross-Linking

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for bone fragility, such as vitamin D, bisphosphonates, and recombinant parathormone, have limitations and side effects, and only moderate efficacy in preventing fractures, necessitating new therapeutic pathways.

Innovation Solution

A dual-target peptide with a specifically designed consensus sequence that binds to and activates both GIP and GLP-2 receptors, enhancing collagen matrix cross-linking and reducing osteoclast formation, is developed for treating bone disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional therapeutic solutions (vitamin D, bisphosphonates, anti-RANKL) are used to treat bone fragility, then some bone protection effect is achieved, but side effects occur and efficacy remains moderate

Engineering Contradiction:

ImproveefficacyVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent combines two incretin hormones (GIP and GLP-1) into a single dual-action peptide molecule. This merged structure allows the peptide to activate both GIP receptors and GLP-1 receptors simultaneously, achieving synergistic bone protective effects while maintaining glucose-dependent insulinotropic activity, thereby improving efficacy without proportionally increasing side effects

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The dual-action peptide serves multiple functions: it acts as both a GIP agonist and a GLP-1 agonist within a single molecule. This multi-functionality allows the peptide to address bone fragility through multiple pathways (bone formation stimulation, bone resorption inhibition, and metabolic regulation) while potentially reducing the need for multiple separate medications and their associated side effects

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If existing bone fragility treatments are administered, then some fractures are prevented, but use restrictions apply and patient monitoring is required

Engineering Contradiction:

Improvefracture preventionVSAvoidadministration flexibility

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent modifies the molecular structure by creating a hybrid peptide that incorporates amino acid sequences from both GIP and GLP-1. This parameter change in molecular composition enables the peptide to bind to and activate both GIP and GLP-1 receptors, providing broad-spectrum bone protection that may reduce the need for strict patient selection criteria and monitoring requirements associated with conventional monospecific therapies

Inventive Principle:

Principle #35Parameter changes

3Reliability

If single-target peptides (GIP or GLP-1 alone) are used, then bone remodeling is modulated, but efficacy is limited compared to dual-target approach

Engineering Contradiction:

Improvebone remodeling modulationVSAvoidenzymatic cross-linking efficiency

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The dual-action peptide merges the active sequences of GIP and GLP-1 into a single chimeric molecule. This merging enables simultaneous activation of both GIP receptors (which stimulate osteoblast activity and collagen cross-linking) and GLP-1 receptors (which inhibit osteoclast formation and bone resorption), resulting in enhanced enzymatic cross-linking efficiency and superior bone remodeling modulation compared to single-target peptides

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The peptide increases collagen matrix cross-linking and reduces osteoclasts more effectively than native peptides, offering a promising treatment for bone fragility and disorders.

Implementation Method 1

a peptide bearing a specifically designed consensus sequence was capable to bind to and activate both glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide 2 (GLP-2) receptor

Methodology Applied

Scientific EffectReceptor binding:

Implementation Method 2

this dual-target peptide increased enzymatic cross-linking of collagen matrix produced by osteoblasts at a higher level than each native peptide

Methodology Applied

Scientific EffectEnzymatic cross-linking: Enzyme

Implementation Method 3

reduced the number of generated osteoclasts in a more important way than each native peptide

Methodology Applied

Scientific EffectCell formation inhibition:

Data Source

PatentUS12617831B2Peptide targeting GIP and GLP-2 receptors for treating bone disorders

Publication Date: 2026.05.05 UNIVERSITE D ANGERS

AI summary

Disclosed is an isolated peptide including the consensus amino acid sequence SEQ ID NO: 1:(SEQ ID NO: 1)HGEGSFX7SDX10 SX12X13LDKLAARDFVNWLLQTKwherein X7 is any amino acid residue, X10 is any amino acid residue, X12 is any amino acid residue and X13 is any amino acid residue. Also disclosed are methods of using such peptide in the treatment of bone disorders.